课题基金 / 基金详情

SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK

SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK
补充工作 - SARS-COV-2 临床前工作
批准号：
10259992
负责人：
LAURIE SOWER
金额：
$150.02万
依托单位：
CHRYSALIS BIOTHERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
项目状态：
已结题
起止时间：
2020-06-05 至 2021-05-31
来源：
https://reporter.nih.gov/project-details/10259992
关键词：
2019-nCoVAcute Lung InjuryAddressAdult Respiratory Distress SyndromeAdverse effectsBiological AssayCOVID-19ClinicalClinical TrialsDocumentationDoseEndotheliumEquipment and supply inventoriesHumanInfectionInflammationNormal tissue morphologyPatientsPharmaceutical PreparationsPhase I Clinical TrialsPhase II Clinical TrialsSARS coronavirusSafetyScheduleWorkhuman subjectpreclinical studypreventregenerativetissue regeneration

项目摘要

项目成果

LAURIE SOWER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Chrysalis proposes to repurpose their regenerative drug, TP508, to treat COVID-19, due to its ability to reduce effects of acute lung injury, prevent normal tissue damage and reduce inflammation. TP508 has an existing efficacy profile in tissue regeneration clinical trials, an extensive safety profile (600 human subjects with no adverse effects), and is GMP manufactured with sufficient inventory to enter COVID-19 clinical trials. The drug addresses underlying causes of ARDS, including loss of endothelial function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION
  • 批准号：
    9915752
  • 项目类别：
  • 资助金额：
    $186.49万
  • 财政年份：
    2019
  • 负责人：
    LAURIE SOWER
  • 依托单位：
    CHRYSALIS BIOTHERAPEUTICS, INC.
A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION
  • 批准号：
    9570138
  • 项目类别：
  • 资助金额：
    $160.54万
  • 财政年份：
    2017
  • 负责人：
    LAURIE SOWER
  • 依托单位：
    CHRYSALIS BIOTHERAPEUTICS, INC.
IGF::OT::IGF TP508 MITIGATES RADIOTHERAPY-INDUCED TISSUE DAMAGE - PERIOD OF PERF
  • 批准号：
    8742630
  • 项目类别：
  • 资助金额：
    $149.99万
  • 财政年份：
    2013
  • 负责人：
    LAURIE SOWER
  • 依托单位：
    CHRYSALIS BIOTHERAPEUTICS, INC.
海外基金